Uppsala, Sweden, 1 September 2015
Beactica, the Swedish fragment-based drug discovery company, today announced its move into new premises at the Uppsala Business Park.
"The move to the new premises give us excellent opportunities to expand as the company grows.” said Beactica’s COO, Dr Malin Elinder. "Our international collaboration partners will also be able to reach us quickly from Stockholm Arlanda Airport.”
The move to Uppsala Business Park establishes Beactica in customised premises in a creative environment for expanding companies. Other Life Science companies in the area include for example Orexo, Fresenius Kabi, Thermo-Fisher and Kemwell.
Beactica moved to Uppsala Business Park on the 1st September 2015.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 560880.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes, Beactica offers expertise and services in the area of SPR biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery.
Sign up for the Beactica newsletter to receive our latest news and updates